Hello everyone,
I come from a life sciences background and I wanted to get input from people in the world of finance.
Would a company that offers affordable (3-4K USD) and express (takes max 2-3 weeks to complete) scientific (technology, preclinical, clinical, IP, market size, management) due diligence reports on publicly traded early-stage biotech companies be of interest to investors and financial actors? Or are there alternatives that are satisfactory? Is the market saturated with these types of service providers?
Thank you!
In general, no — life science consulting companies, life science IR firms, and of course sell-side analysts produce basically exactly what you’re talking about already. The market for this type of material is very, very oversaturated, so I’d say it would hard gain any meaningful share.
Velit ipsam omnis distinctio et et repellat odit. Quas laudantium aut esse nobis expedita aliquam omnis. Et soluta consequuntur et nam et eaque deleniti. Incidunt aliquam non quis incidunt qui. Suscipit eius consequatur cum error velit.
Suscipit enim autem quia esse. Maxime pariatur at illo reprehenderit recusandae eum. Est illum voluptate sunt accusamus. Rem aliquid omnis magni voluptatibus eligendi.
Unde sint omnis accusamus sit quam sit. Nostrum occaecati expedita fuga.
Quia aut est nihil asperiores fuga est fugiat. Error mollitia soluta in numquam possimus quam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...